载脂蛋白AI与载脂蛋白B100检测在肝炎后肝硬化并发门脉高压患者中的临床意义  

The Clinical Significance of ApoAⅠand ApoB100 Determination in Patients with Posthepatitic Cirrhosis Complicating Portal Hypertension

作　　者：陈树添 林章礼 吴伟聪 

机构地区：[1]广东省汕头市第二人民医院检验科,广东汕头515041 [2]汕头大学医学院法医学教研室,广东汕头515041

出　　处：《河北医学》2008年第4期462-464,共3页Hebei Medicine

摘　　要：目的:探讨肝炎后肝硬化并发门脉高压患者载脂蛋白AⅠ(ApoAⅠ)和载脂蛋白B100(ApoB100)水平的临床意义。方法:肝炎后肝硬化并发门脉高压患者和正常对照组各48例,空腹12h后,收集其清晨静脉血2ml,采用HITACHI7180A型全自动生化分析仪,分别测定血清ApoAⅠ、ApoB100水平。结果:患者ApoAⅠ和ApoB100水平较对照组检测结果显著下降(P<0.01)。结论:ApoAⅠ、ApoB100的水平变化可以较准确反应肝炎后肝硬化并发门脉高压患者的肝细胞受损的严重程度,可作为判断其病变及预后的辅助手段。Objective： To explore the clinical significance of determination of ApoA I ,ApoBl00 in patients with posthepatitic cirrhosis complicating portal hypertension. Method： 48 patients with posthepatitic cirrhosis complicating portal hypertension ,48 health persons as Sham group, on an empty stomach 12 hours latter, the vein blood 2ml were collected in the morning, through type HITACHI 7180A automatic biochemical analysis machine,checked the levels of ApoA I ,APOBI00 of serum separately. Result： The levels of ApoA I ,ApoBl00 of serum in patients with posthepatitic cirrhosis complicating portal hypertension were much lower than those in the Sham group（P 〈0.01 ）. Conclusion： The levels of APOA I ,ApoB100 may indicate the damage degree of liver cells in patients with posthepatitic cirrhosis complicating portal hypertension exactly,and may regard as supplementary methods to decide the process and prognosis of the patients.

关 键 词：载脂蛋白 肝硬化 门脉高压 

分 类 号：R575.2[医药卫生—消化系统]